InvestorWire NewsRoom

Articles

Articles Category: Hemp
Tuesday Mar 21, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust RD Programs

Lexaria Bioscience is a global innovator in drug delivery platforms The company has been developing and commercializing patented DehydraTECH(TM), a technology that has been shown to increase the bioavailability of fat-soluble active molecules, improve the speed of onset and provide other benefits across multiple applications Lexaria has undertaken numerous R&D programs in an effort to build relationships with prospective corporate partners to out-license the technology…

Continue Reading

Tuesday Mar 14, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats The success of this DIAB-A22-1 study marks a significant milestone for…

Continue Reading

Friday Mar 10, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension

The global antihypertensive drugs market was valued at around $20.5 billion in 2021 and is expected to reach $39.5 billion by 2030, growing at a CAGR of 2.95% Lexaria’s patented DehydraTECH(TM) technology is designed to formulate and deliver lipophilic drugs and active pharmaceutical ingredients (“APIs”), increasing effectiveness and improving how drugs are delivered into the bloodstream DehydraTECH is suitable for use with a wide range…

Continue Reading

Tuesday Mar 07, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology

Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits,…

Continue Reading

Thursday Mar 02, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation

Lexaria's DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures Lexaria is conducting early work to support its FDA-registered IND…

Continue Reading

Wednesday Mar 01, 2023 - 10:30 am

Prime Harvest Inc. Reveals That Their Reg A+ Equity Offering Has Been Granted Approval to Go Ahead

Prime Harvest recently revealed that the company’s Reg A+ equity offering has been greenlighted by the SEC The primary share offering will see the company market up to 10 million shares to investors at a price of $4.20 each, with estimated gross proceeds of $42 million The company has said that net proceeds will be destined towards the acquisition of licensed assets, continued expansion of…

Continue Reading

Monday Feb 27, 2023 - 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD

Dosing for Lexaria’s ambitious and most comprehensive clinical study, HYPER-H21-4, was successfully completed in July 2022, with newly analyzed results now emerging Its latest findings bring the company closer to its upcoming FDA Phase 1b study while also explaining the patented DehydraTECH-(TM)-processed CBD interaction with the sympatho-chromaffin system via catestatin modulation Lexaria’s management is optimistic that DehyraTECH-CBD and its effectiveness in modulating catestatin levels could…

Continue Reading

Thursday Feb 23, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking Forward to 2023 Goals for Patented DehydraTECH(TM) Technology

Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world's leading anti-seizure medications During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes…

Continue Reading

Wednesday Feb 22, 2023 - 11:15 am

Alternative Products Expo Announces Its Upcoming Fort Lauderdale 2023 Show

Alternative Products Expo has just announced its next show, which will take place on March 3-5, 2023, in the beautiful city of Fort Lauderdale, Florida. This one-of-a-kind trade show promises to provide attendees with a unique experience that breaks away from the monotony of traditional events. It's a must-attend for anyone in the smoke shop and counterculture industry. Known for short as Alt Pro Expo,…

Continue Reading

Tuesday Feb 21, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities

Lexaria’s patented DehydraTECH(TM) technology improves how APIs enter the bloodstream through the promotion of healthier oral ingestion methods while also increasing the effectiveness of fat-soluble active molecules As a disruptive technology, its impact has been felt by other players in its space, leading Lexaria to open its doors to partnering with industry experts and implementing the technology across many fields, including licensing the technology to…

Continue Reading

Friday Feb 10, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study

In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28…

Continue Reading

Wednesday Feb 08, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes The technology is also expected to lower the overall drug costs because it delivers more…

Continue Reading

Monday Feb 06, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage…

Continue Reading

Friday Jan 27, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program…

Continue Reading

Wednesday Jan 25, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through…

Continue Reading

Wednesday Jan 11, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost…

Continue Reading

Monday Jan 09, 2023 - 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure The company also reported that…

Continue Reading

Friday Jan 06, 2023 - 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies…

Continue Reading

Wednesday Jan 04, 2023 - 11:15 am

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase…

Continue Reading

Wednesday Dec 28, 2022 - 9:00 am

M&A Activity Keeps Flora Growth Corp. (NASDAQ: FLGC) Revenues Strong Amid Expected Rebound in Cannabis Industry

Cannabis cultivator and international brand developer Flora Growth has continued to build its revenues through accretive acquisitions during the past year and expects to see revenues continue to rise amid further M&A activity Flora expects to lock in its latest acquisition by the end of the month after shareholders meet to discuss the proposed deal with multi-national operator Franchise Global Health (“FGH”), which would grant…

Continue Reading

Tuesday Dec 27, 2022 - 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals

Studies have indicated that around 40% of the available drugs on the market offer poor bioavailability Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery The global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value…

Continue Reading

Thursday Dec 22, 2022 - 9:00 am

Luis Merchan, Helping Flora Growth Corp. (NASDAQ: FLGC) Become Global Leader in the CBD Space

Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022 Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue  Under…

Continue Reading

Thursday Dec 15, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be…

Continue Reading

Tuesday Dec 13, 2022 - 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements Lexaria started and completed its fourth and most comprehensive hypertension study yet,…

Continue Reading

Wednesday Dec 07, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research program The program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drug The first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than Epidiolex The second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted…

Continue Reading

Friday Dec 02, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forward With Exploration of Patented DehydraTECH(TM)-Processed CBD for Dementia

Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030 The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029 Clinical studies have established a connection between hypertension and dementia With DehydraTECH(TM)-CBD already evidencing that it can…

Continue Reading

Tuesday Nov 29, 2022 - 1:30 pm

Prime Harvest Inc. Positioned to Lead California’s Cannabis Market with Direct-to-Consumer Expansion

Prime Harvest is the parent company of Jaxx Cannabis, its D2C operations actively expanding throughout California Prime Harvest’s brand partners strongly positioned across multiple segments of the cannabis value chain Brand partners include Mary's Medicinals, STIIIZY, Lime Cannabis, and Tonik Revenue diversification is critical to sustainable growth in the cannabis industry, and it’s central to the strategy of Prime Harvest, a technology-focused, full-service cannabis corporation.…

Continue Reading

Tuesday Nov 29, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of…

Continue Reading

Wednesday Nov 23, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementiaThe animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancementsPrevious independent studies have shown that CBD prevents the development of a social recognition deficit,…

Continue Reading

Monday Nov 21, 2022 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetesThe company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetesLexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and…

Continue Reading

Thursday Nov 17, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Approved to Proceed with Human Study Evaluating Effectiveness of Patented DehydraTECH(TM) Technology in Boosting Oral-Tissue Absorption of Nicotine

Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soonThe company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and ZynLast year, Lexaria conducted an animal study evaluating…

Continue Reading

Friday Nov 11, 2022 - 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placeboAccording to a Zacks SCR report, the findings support their $15 share valuation of the companyZacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral productsThe hypertension drug market is expected to grow to over $34 billion through 2030,…

Continue Reading

Wednesday Nov 09, 2022 - 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Defines Path to Profitability and Portfolio Expansion with Proposed Franchise Global Health Inc. Acquisition

Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreementThe deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and…

Continue Reading

Tuesday Nov 08, 2022 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patientsWith the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation. 47% of adults live with hypertension but only 24% of them have it under controlWith its DehydraTECH-CBD, Lexaria hopes to not…

Continue Reading

Monday Nov 07, 2022 - 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern ColombiaFlora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprintFGH is focused on the German market, where its subsidiary was the first company to sell…

Continue Reading

Friday Nov 04, 2022 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing causeLexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosingThe global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%,…

Continue Reading

Thursday Nov 03, 2022 - 10:30 am

Tampa Alternative Products Expo Brings Together The Local Community For Three Days of Festivity And Business Networking

After various successful shows across North and South America, Alternative Products Expo is coming to Tampa, Florida, this November 10-10, at Tampa's Convention Center. The event has something for everyone. It features over 250 industry vendors, 20+ speakers from across the industry, and many contests and giveaways. Starting some years ago with a series of successful Vape events, the Alt Pro Expo team ventured into…

Continue Reading

Thursday Nov 03, 2022 - 9:00 am

Cannabis Regulation in the Spotlight During Midterm Elections at the Heels of Presidential Pardon; Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombian Stance to Manufacture Products at Lower Costs

President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state levelThe President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemicFlora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the…

Continue Reading

Wednesday Nov 02, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD

Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIsHypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancyThe company has received positive…

Continue Reading

Tuesday Nov 01, 2022 - 12:00 pm

Tampa Alternative Products Expo To Offer A Festive Vibe Amongst Business Networking

Exhibitors, speakers, businesses, CBD and alternative products vendors, and researchers, are all invited to attend the Tampa Alternative Products Expo 2022 at the Tampa Convention Center. With over 10,000 attendees, 300+ vendors, and 20+ speakers per event, the Expo will exude a festival-like vibe for Tampa's CBD, cannabis, and vape communities. The event is organized by ZJ Events, with a reputation for managing the nation's…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).